A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler / Robert West (2000)  

Public Titre : A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler Type de document : document électronique Auteurs : Robert West, Auteur ; Peter Hajek, Auteur ; J. Foulds, Auteur ; Fredrik Nilsson, Auteur ; Sylvia May, Auteur ; Anna Meadows, Auteur Editeur : Springer Année de publication : 2000 Collection : Psychopharmacology num. 149(3) Importance : p.198-202 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:chewing-gum [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:inhalateur [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:spray nasal [TABAC] tabagisme:dépendance tabagique:dépendance psychologique [TABAC] tabagisme:évaluation du tabagisme:test de dépendance à la nicotine Index. décimale : TA 6.2.3.1 Substitution nicotinique Résumé : Rationale: Nicotine replacement therapy (NRT) in varying forms is becoming widely used. Clinicians, therapists and regulatory authorities are interested in the abuse liability and dependence potential of the different forms. Objectives: To compare the abuse liability and dependence potential of nicotine gum, transdermal patch, spray and inhaler. Methods: 504 male and female smokers seeking help with stopping smoking were randomly allocated to the four products. Measures were taken at the designated quit date, then 1 week, 4 weeks, 12 weeks and 15 weeks later. Smokers were advised to use the product for up to 12 weeks. Those still using the product at the 12-week visit were advised to cease use by week 14. Measures included: pleasantness and satisfaction ratings at weeks 1 and 4 (used as a marker of abuse liability); ratings of feeling dependent on NRT at weeks 1, 4, 12 and 15 (used as a marker of subjective dependence); mood and physical symptoms ratings at weeks 12 and 15 (the change being used to assess physical dependence on NRT), continued usage of NRT at week 15 (used as an marker of behavioural dependence). Results: Average ratings of pleasantness were low. The nicotine patch was rated as less unpleasant to use than all other products. There were no significant differences between the products in terms of satisfaction or subjective dependence except at week 15 when no patch users rated themselves as dependent. Continued use of NRT at week 15 was related to rate of delivery of nicotine from the products - 2% for patch, 7% for gum and inhaler, 10% for spray (P<0.05 for linear association). Among those En ligne : https://doi.org/10.1007/s002130000382 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10350

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

The neurobiological basis for partail agonist treatment of nicotine dependance / J. Foulds (2006)

Public Titre : The neurobiological basis for partail agonist treatment of nicotine dependance : varenicline Type de document : texte imprimé Auteurs : J. Foulds, Auteur Editeur : John Wiley & Sons Année de publication : 2006 Collection : International journal of clinical practice, ISSN 1368-5031 num. Vol 60, n. 5 Importance : p.571-576 Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract Smoking cessation has major health benefits for men and women of all ages. However, most smokers are addicted to nicotine and fail repeatedly in their attempts to quit. Stimulation of nicotinic receptors in the brain, particularly alpha4beta2 receptors, releases dopamine in the meso-limbic area of the brain and is reinforcing. Nicotine abstinence reduces dopamine release, and this is associated with withdrawal symptoms and craving for nicotine. Eight current pharmacotherapies--bupropion, nortriptyline, clonidine and nicotine patch, gum, inhaler, lozenge and nasal spray--are moderately effective aids to smoking cessation. Each is significantly better than placebo, but approximately 80% of patients using one of these medications return to smoking within the first year. Varenicline, a specific alpha4beta2 nicotinic receptor partial agonist, is a new pharmacotherapy that stimulates dopamine and simultaneously blocks nicotine receptors. Phase II and III trials have yielded promising results suggesting that varenicline could be an important advance in the treatment of nicotine dependence. Comment in Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7939

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005480	TA 6.2.3.1.4 FOU N	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !